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Squamous cell carcinoma (SCC) of the oesophagus is well recog-
nized for its aggressive biological behaviour, in respect of local
infiltration and metastases to regional lymph nodes and distant
organs (Orrigner, 1997). Extra-oesophageal tumour spread is
present in 70% of cases at the time of diagnosis, and the 5-year
survival is only 3% when lymph node metastases are present,
compared with 42% in lymph node negative patients (Orrigner,
1997). Patients with distant metastasis also have a poor prognosis,
with a 5-year survival rate of 5% or less (Mandard et al, 1984;
Orrigner, 1997).
Metastasis is a multistep process involving complex associa-
tions of tumour cells with host cells or with matrix (Stracke and
Liotta, 1995). Recently, genetic mechanisms underlying metas-
tasis and pathogenesis of oesophageal SCC have been explored in
several studies: int-2/hst-1 co-amplification correlated with high
incidence of metastasis in distant organs (Kitagawa et al, 1991),
loss of heterozygosity of the DCC gene associated with the degree
of lymph node metastasis (Miyake et al, 1994), and mutation of
the p53 gene in the pathogenesis (Hollstein et al, 1990; Meltzer et
al, 1991) of SCC. However, there are only a limited number of
reports on the prognostic indicators for invasion and metastasis of
oesophageal SCC.
Metallothioneins (MTs) have been described in most vertebrate
and invertebrate species as low molecular weight proteins.
Overexpression of MT was described in a variety of human
tumours, in relation to different stages of tumour development and
progression (Jasani and Schmid, 1997). MT was considered as a
potential prognostic marker in invasive ductal carcinoma of the
breast by Schmid et al (1993) and others (Fresno et al, 1993;
Goulding et al, 1995, Oyama et al, 1996). In skin carcinoma
(Zelger et al, 1994), melanoma (Zelger et al, 1993), cervical carci-
noma (Lim et al, 1996) and pancreatic carcinoma (Ohshio et al,
1996), MT overexpression appears to be predominantly associated
with more advanced, highly malingant tumours. To the contrary,
Öfner et al (1994) reported that MT overexpression in colorectal
carcinoma was associated with better clinical outcome and tumour
stages. Therefore, MT overexpression may be paradoxically asso-
ciated in some tumours with better clinical outcome.
Tumour MT level also has been reported to correlate with resis-
tance to anticancer reagents (Kelley et al, 1988; Kasahara et al,
1991; Chin et al, 1993; Kondo et al, 1995; Hishikawa et al, 1997).
In oesophageal SCC, we already reported that MT protein expres-
sion might be a significant determinant of prognosis, in particular,
associated with cisplatin resistance (Hishikawa et al, 1997).
Patients with MT protein-negative tumours survived longer when
treated with cisplatin than those with MT protein-positive
tumours. However, the exact biological significance of the expres-
sion of MT protein and mRNA is largely unknown in the clinical
setting of oesophageal SCC.
Therefore, in the present study, we have investigated the expres-
sions of both MT mRNA and its protein in surgically resected
oesophageal SCC by in situ hybridization and immunohistochem-
istry, respectively, and addressed whether MT expression could
predict the prognosis and metastatic potential of oesophageal SCC
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without any pretreatment. Moreover, we have attempted to corre-
late the expression of MT with proliferating cell nuclear antigen
(PCNA) expression, since in gastrointestinal tumours significant
correlation have been noticed between proliferative activity and
metastatic potential (Hall et al, 1990; Jain et al, 1991; Al-Sheneber
et al, 1993; Hickey et al, 1994; Kinugasa et al, 1996).
MATERIALS AND METHODS
Patients
Between 1984 and 1994, 152 patients with oesophageal SCC were
treated in the Second Department of Surgery, Shimane Medical
University. Fifty-seven patients who were not treated with pre-
operative adjuvant therapies were selected for the analysis of MT
mRNA by in situ hybridization, and that of MT protein and PCNA
by immunohistochemistry. Ninety-five patients were excluded
because of non-resectable tumours due to either disease that was
too advanced or poor general conditions, death by surgical compli-
cations, preoperative adjuvant therapy for the tumour which might
be induced MT, and early-stage diseases (carcinoma in situ).
Thirty-six of the 57 patients received systemic chemotherapy
and/or external radiotherapy postoperatively. Twenty-three
patients of them were treated with cisplatin, 5-fluorouracil (5-Fu)
and radiotherapy. Eight patients received cisplatin and 5-Fu
without radiotherapy, and five patients received radiotherapy
alone. Staging of the disease was based on the TNM staging
system (UICC, 1992). Patients’ clinicopathological characteristics
are shown in Table 1. All patients or their next of kin provided
informed consent for participation in the clinical study.
Tissue preparation
The surgical specimens were fixed in 10% buffered formalin solu-
tion and embedded in paraffin. The same paraffin-embedded block
was used for in situ hybridization and immunohistochemistry. Five
micron-thick sections were mounted on aminopropyltriethoxyl-
silane-coated glass slides.
Oligo-DNAs
The oligo-DNA probe sequences of human MT for in situ
hybridization were shown in Table 2. MT exists in different
isoforms and most human MT genes, including the mainly func-
tional ones (MT IA and MT IIA), are localized on chromosome 16
(Karin et al, 1984; Le Beau et al, 1985), and MT IIA is the major
human MT gene, accounting for 50% of the MT mRNA expres-
sion. Then, to screen MT-positive cases, we used common
oligonucleotide sequences shared among MT genes (93–98%
homology) as a general MT probe set. The MT antisense oligo-
DNA using thymine-thymine (T-T) dimerized DNA as a haptenic
probe was selected complementary to the mRNA sequence coding
for amino acids of the human MT IIA protein (Karin and Richards,
1982) and the MT sense oligo-DNA corresponded to the mRNA
sequence (Table 2A). These two oligo-DNAs were added with
three and two repeats of adenine-thymine-thymine (ATT) at the 5¢
and 3¢ ends, respectively, for the T-T dimers. We conducted a
computer-assisted search (GenBank nucleic acid sequence data-
base Release 102.0) of the above MT IIA oligo-DNA sequences
(without the ATT repeats) and found 100% homology with MT
IIA mRNA sequence and 93% with MT IA mRNA sequence.
Therefore, to distinguish the MT IA and MT IIA mRNAs
completely, we performed a second set of experiment with target
sequences in MT IA and MT IIA mRNAs closer to the 3¢ end of
the message, where significant dissimilarities between mRNAs
encoding different MT isoforms exist (Table 2B).
Labelling and detection of oligo-DNAs
The MT oligo-DNAs were haptenized by introducing T-T dimers
by UV irradiation as described in detail previously (Koji and
Nakane, 1996). The optimal UV dose for these oligo-DNAs was
10 000 J m–2 as determined by dot-blot hybridization, described
below. Both the MT IA and MT IIA oligo-DNAs were labelled at
their 5¢- and 3¢-end with digoxigenin (Dig)-11-dUTP by terminal
deoxynucleotidyl transferase as described in detail previously
(Koji and Brenner, 1993). The detection sensitivity of the T-T
dimerized DNAs was examined immunohistochemically by using
a HRP-linked mouse anti-T-T IgG (Kyowa Medex, Japan) and that
of the Dig-labelled ones was done by using an anti-Dig-POD anti-
body (Boehringer Mannheim, Germany).
Dot-blot hybridization
The procedures for dot-blot hybridization were described previ-
ously in detail (Yoshii et al, 1995; Koji and Nakane, 1996). Two
microlitres of the sense oligo-DNA solution were placed on nitro-
cellulose membranes that had been pretreated with 20 ´ SSC (1 ´
SSC = 0.15 M sodium chloride and 0.015 M sodium citrate, pH 7.0)
in a series of spots from 1 pg to 10 ng per spot. The membranes
were hybridized at 42°C for 15–17 h with 2 mg ml–1 T-T dimerized
MT antisense probe or T-T dimerized MT sense probe. After
successive washing, the membranes were immersed in a blocking
solution for 1 h. The reaction with mouse anti-T-T IgG (diluted at
1:80 with the blocking solution) was performed for 3 h. After
washing with phosphate-buffered saline (PBS), visualization of
HRP sites was performed with diaminobenzidine–4 hydrochloric
acid (DAB), H2O2, Co2+, and Ni2+ according to Adams (Adams,
1981).
Table 1 Clinicopathological characteristics of the 57 patients
Values
Sex (male/female) 53/4
Age, years (mean ± s.d.) 63.7 ± 8.5
Tumour location
Upper/middle/lower 9/27/21











Cisplatin + 5-FU + radiation 23
Cisplatin + 5-FU 8
Radiation 5
No treatment 21714 Y Hishikawa et al
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In situ hybridization
To estimate the amount of RNA retention level in paraffin
sections, methyl green–pyronin Y staining (Shulte et al, 1992) was
used before performing in situ hybridization in every run. The
procedures for pretreatments were described previously in detail
(Koji and Brenner, 1993; Koji and Nakane, 1996). Briefly, the
sections were deparaffinized and rehydrated according to the
standard procedures. These sections were treated with 0.2 N
hydrochloric acid (RT, 20 min) and digested with 25 mg ml–1 of
proteinase K (37°C, 15 min). After post-fixation with 4%
paraformaldehyde in PBS (5 min), the sections were immersed in
2 mg ml–1 glycine in PBS (15 min) twice and kept in 40% de-
ionized formamide in 4 ´ SSC until used for hybridization.
Hybridization was carried out at 42°C for overnight with 
2 mg ml–1 T-T labelled oligo-DNA probes or with 2 mg ml–1 Dig-
labelled oligo-DNA probes dissolved in the hybridization medium.
After repeated washings, the signals were detected by enzyme-
immunohistochemistry as described above, without any counter-
staining.
Control experiments
To confirm the specificity of MT mRNA signals, we conducted
various types of control experiments concurrently with the test
experiments. First, the sense probe was used as a negative control
in every run. To evaluate the level of hybridizable RNAs in tissue
sections, duplicate serial sections were used for 28S rRNA probe
as a positive control in every case (Yoshii et al, 1995).
Furthermore, some sections were hybridized with MT mRNA anti-
sense probe in the presence of an excess amount of either homolo-
gous or heterologous unlabelled oligo-DNA to provide definitive
evidence for the sequence specificity of the signal as described
previously in detail (Koji and Brenner, 1993). To eliminate
possible involvement of proteins and DNA in signal information,
some sections were digested with RNase (100 mg ml–1, 37°C, 1 h)
before the post-fixation step (Koji and Brenner, 1993).
Immunohistochemistry
Immunohistochemical staining was performed by the streptavidin–
biotin (SAB) method using the SAB kit (Nichirei, Japan) according
to the standard procedures. The monoclonal mouse anti-MT antibody
(E9; Dako, USA) to an epitope of MT shared by its I and II isoforms
of human, rat, horse MT was used at 1:100 dilution for 30 min at
room temperature. This antibody has been used successfully to detect
immunoreactive MT in formalin-fixed, paraffin-embedded tissues of
human origin (Jasani and Elmes, 1991). To study the expression of
PCNA, a mouse monoclonal antibody to PCNA (PC10; Dako,
Denmark) was used at 1:100 dilution for 2 h at room temperature.
AEC kit (Nichirei, Japan) for MT expression and DAB kit (Nichirei,
Japan) for PCNA expression were used to visualize the sites of HRP.
As positive control for MT staining, normal human colonic mucosa,
which was already reported to express MT (Mulder et al, 1990;
Steele et al, 1990) was used. To ensure consistency of PCNA
staining, a known positive control oesophageal carcinoma was
included in each run (Kinugasa et al, 1996). For the negative control,
normal mouse IgG was used instead of the primary antibody.
Statistical analysis
Mean values were compared with unpaired Student’s t-test, and
categorical variables were compared with Fisher’s exact probability
test. Actuarial survival was calculated by the Kaplan–Meier
method and statistically evaluated by the log-rank test. Multivariate
regression analysis was performed using step-wise multiple regres-
sion test among different clinical pathological factors. A P-value 
of less than 0.05 was considered statistically significant. All the
analyses were performed with a statistical software package (Stat
View, ver. 4.51; Abacus Concepts, Berkely, CA, USA).
Table 2 The oligo-DNA probe sequences of human MTa for in situ hybridization
(A) T-T dimerized MT probe
antisense oligo-DNA probe
** ** b ** ** **
5¢ : TTATTA-CCT GGG CAC ACT TGG CAC AGC CCA CAG GGC AGC AGG AGC AGC AGC-ATTATTATT: 3¢
sense oligo-DNA probe
** ** b ** ** **
5¢ : TTATTA-GCT GCT GCT CCT GCT GCC CTG TGG GCT GTG CCA AGT GTG CCC AGG-ATTATTATT: 3¢
(B) Digoxigenin-labeled MT probe
antisense oligo-DNA probe
MT IA 5¢ : GTC ACT CTT TCT ATA TCT TCG AGC AGG GCT GTC CGG ACA TCA GGC : 3¢
MT IIA 5¢: GTG GAA GTC GCG TTC TTT ACA TCT GGG AGC GGG GCT GTC CCA GCA : 3¢
sense oligo-DNA probe
MT IA 5¢ : GCC TGA TGT CCG GAC AGC CCT GCT CGA AGA TAT AGA AAG AGT GAC : 3¢
MT IIA 5¢ : TGC TGG GAC AGC CCC GCT CCC AGA TGT AAA GAA CGC GAC TTC CAC : 3¢
aMT, metallothionein; T-T, thymine-thymine. b**, possible sites of T-T dimers.
10 ng 1 ng 100 pg 10 pg 1 pg
Antisense
Sense
Figure 1 Dot-blot hybridization. Various amounts (1 pg to 10 ng per spot) of
MT sense oligo-DNA were hybridized with T-T-labelled MT antisense oligo-
DNA (upper panel) or T-T labelled MT sense oligo-DNA (lower panel). Ten pg
DNA was detected specifically.Metallothionein in oesophageal SCC 715
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RESULTS
Dot-blot hybridization with T-T dimerized oligo-DNA
When T-T dimerized MT antisense probe was hybridized with
unhaptenized MT sense oligo-DNA fixed on a nitrocellulose filter,
10 pg of oligo-DNA was detectable (Figure 1). However, with the
sense probe no staining was found. For all probes used in the
present study, similar results were obtained (data not shown).
These findings indicated that the antisense probes we synthesized
were specific and had adequate sensitivity to be useful for in situ
hybridization studies.
Localization of MT mRNA by in situ hybridization
The staining intensities for MT mRNA were graded as negative, no
staining or positive, weak and intense staining, as compared to that
with sense probe. MT mRNA expression for using T-T dimer as a
general MT probe set was detected in 38 of the 57 patients (Figure
2A). As a negative control, when a section was hybridized with 
T-T-dimerized MT sense probe, no signal were observed (Figure
2B). Therefore, as the next step, in situ hybridization with specific
probes to MT IA and MT IIA was performed to distinguish
between the MT IA and MT IIA mRNAs in the MT mRNA-posi-




Figure 2 In situ hybridization in paraffin sections of oesophageal
SCC. (A), MT antisense T-T dimerized oligo-DNA probe. (B), MT
sense T-T dimerized oligo-DNA probe. (C), MT IIA antisense Dig-
labelled oligo-DNA probe. MT IIA signal was most intensive in the
perinuclear area. (D), MT IIA sense Dig-labelled oligo-DNA probe.
Arrowheads indicate positive staining of MT in oesophageal SCC.
(E), 28S rRNA complementary T-T dimerized oligo-DNA probe.
Original magnification, ´ 50716 Y Hishikawa et al
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were randomly selected for the experiment. MT IIA mRNA expres-
sion was detected in all ten cases (Figure 2C), but MT IA mRNA
expression could not be detected. As a negative control, no staining
was found with Dig-labelled MT IIA sense probe in an adjacent
section (Figure 2D). 28S rRNA probe used as a positive control
gave an intense staining in cancer cells (Figure 2E).
Localization of MT protein by immunohistochemistry
Expression of MT protein using immunohistochemistry was
estimated visually as negative, very weak (scattered positive cells
were less than 5% in the carcinomatous tissue), or positive (stained
cells more than 5%). In the following analyses, patients with very
weakly stained sections were categorized as the negative group.
MT protein was localized in nuclei and/or cytoplasm (Figure 3A).
MT protein expression was detected in 33 of the 57 patients.
Inconsistency of MT mRNA and protein expression
MT mRNA-positive cases were 38 of the 57 patients by in situ
hybridization, and MT protein-positive cases were 33 by immuno-
histochemistry. The inconsistency of MT mRNA and protein
expression was shown in Table 3. Twenty-five of the 57 tumours
were positive, and 11 tumours were negative for MT expression at
both mRNA and protein levels. In 13 tumours MT was detectable
only at the mRNA level, whereas in the remaining eight tumours it
was detected only at the protein level.
Correlation of MT expression with metastasis and
patient’s survival
Comparisons were made between MT mRNA and MT protein
expressions and the following variables: age, sex, tumour length,
tumour location, histological differentiation, stage (TNM), lymph
node metastasis (N0; no lymph node metastasis, or N1; regional
lymph node metastasis) and distant metastasis (M0; no distant metas-
tasis, or M1; distant metastasis). Only significant factors of this
analysis have been shown in Table 4. The proportion of lymph node
metastasis was 71% in patients with MT mRNA-positive tumours
and 42% in those with MT mRNA-negative tumours (P = 0.0343).
The proportion of distant metastasis was 29% in MT mRNA-positive
patients and 5% in MT mRNA-negative patients (P = 0.0452).
Similarly, in respect of MT protein expression, the frequency of
distant metastasis was more common in MT protein-positive tumours
than in MT protein-negative tumours (30% versus 8%; P = 0.0446).
The patients with MT protein-negative tumours survived better
than those with MT protein-positive tumours (P = 0.0340; 95%
confidence interval for MT negative, 0.522–0.911, and for MT
positive, 0.161–0.518) (Figure 4). Survival rate between the
patients with MT mRNA-negative and -positive tumours,
however, was not significantly different (data not shown).
MT expression and its relation to cell proliferation
assessed by PCNA immunostaining
Fifty of the 57 patients were selected for the evaluation of PCNA
staining because of the adequate nuclear form and low back-
ground. The staining was judged as positive when cancer cell
nuclei were stained in equal intensity to the parabasal cells in
normal oesophageal epithelium (Figure 3B). On average, we
counted at least 1000 nuclei in randomly selected ten high power
fields in each specimen. PCNA staining varied within a range of
0–48% with a mean value ± s.d. (16.7 ± 12.0), so the lower cut-off
point for PCNA positivity was 5% of the ratio of positive nuclei.
In 28 of the 50 cases, which were satisfactorily evaluated for both
PCNA and MT protein expressions, 93% of cases with both PCNA
and MT protein expressions were mainly observed at the invasive
edge of the tumour, as shown in serial sections stained by anti-MT
and anti-PCNA (Figure 3A and 3B). Correlation of MT and PCNA
AB
Figure 3 Immunohistochemical staining of (A) MT protein and (B) PCNA in paraffin sections of oesophageal SCC. Arrows indicate positive staining both MT
protein and PCNA expressions in the same area of the invading edge of the tumour. Original magnification, ´ 50
Table 3 Inconsistency of MT mRNA and protein expression
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expression is shown in Table 5. A higher percentage rate of nuclear
staining for PCNA antigen was observed in MT protein-positive
tumours than in those -negative tumours (P = 0.0018). All MT
protein-positive tumours were in the PCNA-high tumours group (P
< 0.0001). On the other hand, the rate of PCNA expression was not
different between lymph node metastasis (N0 = 14.7 ± 13.9% versus
N1 = 18.1 ± 10.6%; P = 0.3331) and distant metastasis (M0 = 15.1 ±
12.3% versus M1 = 23.0 ± 8.3%; P = 0.0590).
Survival rates according to the expression of MT protein and
PCNA are shown in Figure 5. The patients with MT protein-negative/
PCNA-low tumours survived better than those with MT protein-
negative/PCNA-high and MT protein-positive/PCNA-high tumours
(P = 0.0343; 95% confidence interval for MT-negative/PCNA low,
0.739–1.079, for MT-negative/PCNA-high, 0.201–0.889, and for
MT-positive/PCNA-high, 0.140–0.514).
Table 4 Significant factors of clinicopathological characteristics of MTa mRNA and MT protein expression
MT mRNA MT protein
Negative Positive P-value Negative Positive P-valueb
Factors (n = 19) (n = 38) (n = 24) (n = 33)
Lymph node metastasis (N)
N0 11 11 0.0343 12 10 0.1315
N1 8 27 12 23
Distant metastasis (M)
M0 18 27 0.0452 22 23 0.0446
M1 1 11 2 10
aMT, metallothionein; N0, no regional node metastasis; N1, regional node metastasis; M0, no distant metastasis; M1, distant metastasis. bFisher’s exact
probability test.
Table 5 Correlation between MTa and PCNA expression
MT mRNA MT protein
Negative Positive P-value Negative Positive P-value
(n = 17) (n = 33) (n = 22) (n = 28)
PCNA (%, mean ± SD) 18.5 ± 19.8 16.7 ± 10.6 0.6777 10.9 ± 11.5 21.2 ± 10.5 0.0018b
Evaluation of PCNA
Low 5 6 0.3638 11 0 <0.0001c
High 12 27 11 28
















































Figure 4 The survival curves of MT protein-negative and -positive tumours.
The patients with MT protein-negative tumours survived better than those
with MT protein-positive tumours (P = 0.0340; 95% confidence interval for
MT-negative, 0.522–0.911, and for MT-positive, 0.161–0.518)
Figure 5 The survival curves of combined MT protein and PCNA
expression. The patients with MT protein-negative/PCNA-low tumours
survived better than those with MT protein-negative/PCNA-high and MT
protein-positive/PCNA-high tumours (P = 0.0343; 95% confidence interval for
MT-negative/PCNA-low, 0.739–1.079, for MT-negative/PCNA-high,
0.201–0.889, and for MT-positive/PCNA-high, 0.140–0.514)718 Y Hishikawa et al
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Multivariate analysis
Multivariate analysis was conducted among the different clinico-
pathological variables by using step-wise multiple regression test.
Tumour size (> 6 cm or 6 cm; ³ P < 0.0001), lymph node metas-
tasis (N0 or N1; P = 0.0133), and distant metastasis (M0 or M1;
P = 0.0353) were independent prognostic factors for overall
survival. Patient’s age, gender, histological differentiation, post-
operative therapies (treated or not; cisplatin, 5-FU, radiation), and
staining intensity of MT protein and that of PCNA were not found
to be an independent predictor of prognosis.
DISCUSSION
In the present study, we have investigated the expression of MT
mRNA and its protein in oesophageal SCC by non-radioactive in
situ hybridization and immunohistochemistry respectively. As a
result, we have found that MT expression is correlated with high
incidence of tumour metastasis in patients with oesophageal SCC.
In fact, we previously reported that the expression of MT protein
in SCC of the oesophagus could be a significant determinant of
poor prognosis in patients with cisplatin (Hishikawa et al, 1997).
In the previous study, however, we could not avoid the possible
effect of preoperative adjuvant therapies on the expression of MT.
Therefore, we confirmed here the previous findings in the patients
without preoperative treatment and also extended our analysis of
MT expression to its transcript level.
The human MT mRNAs for MT I and MT II are highly homol-
ogous and substantial cross-hybridization with transcripts of other
MT isoforms can be expected with the conventional probes. First,
we searched the positivity of MT mRNA expression using first set
oligo-DNA probe (T-T dimered one), and the expression of MT
mRNA in oesophageal SCC was found in 66.6% of our patients.
Therefore, we chose more specific target sequences for MT IA and
MT IIA mRNAs closer to the 3¢ end of the message further to
confirm the specific expression of MT IA and MT IIA mRNAs.
About ten MT mRNA-positive cases were randomly selected. MT
IIA mRNA expression was found in all cases and MT IA mRNA
expression was not detectable in any of these cases. Therefore, it is
suggested that the expression of MT mRNA, mainly MT IIA
mRNA, might be associated with the genetic mechanisms under-
lying metastasis in oesophageal SCC.
MT mRNA expression was positively correlated with metas-
tasis to regional lymph nodes, and both MT mRNA and its protein
levels were elevated in cases with distant metastases. Regarding
the induction of MT gene expression, it is well known that MT
gene contains AP-1 site in the regulatory region (Lee et al, 1987)
and the transcription of MT gene is activated in part by this signal-
transduction pathway (Skroch et al, 1991). Hu et al (1994) have
reported that c-fos may play an important regulatory role in the
invasive behaviour of malignant tumours. This oncogene product
forms heterodimers with c-jun protein, and the resulting complex
binds AP-1 sites of DNA and stimulates specific gene transcription
through these elements (Chiu et al, 1988; Ransone and Verma,
1990), implying the possible relationship between MT gene
expression and metastatic activity.
The available information on the character and consequences of
MT overexpression associated with human cancer is presently
limited (Jasani and Schmid, 1997), therefore, the actual role of MT
related to invasiveness and metastasis is largely unknown in the
clinical setting. In a mouse melanoma cell invasion model, it was
shown that heavy metal-induced MT serves as a host-derived
factor for cancer cell metastasis (Haga et al, 1996a). Recently, it
was noted that MT enhances gelatinase A activation and induces
cancer metastasis in vivo (Haga et al, 1996b). The significant
correlation of MT expression with frequent occurrence of lymph
node metastasis in this study indicates that MT might be a host-
related factor for cancer metastasis. Furthermore, in MCF-7 cells,
human breast cancer cell line, transfected with MT antisense
oligonucleotide, the cell growth was remarkably inhibited and
their apoptosis was induced (Abdel-Mageed and Agrawal, 1997).
In the future, it could be possible to regulate the metastatic poten-
tial of the oesophageal SCC by antisense MT gene therapy.
The results obtained for MT protein and mRNA expression
seemed to be inconsistent. Thirty-six of the 57 patients expressed
MT equally at the mRNA and protein level, whereas 21 patients
showed discrepancy. The controversial results in the 21 patients
could be explained in the following ways:
1. there are differences in their half-lives or synthetic rates of
mRNA and protein, so that the level of MT mRNA expression
is not always directly proportional to that of MT protein
(Skroch et al, 1991; Tohyama et al, 1993)
2. MT expression may be regulated at the post-transcriptional level.
This post-transcriptional control of MT expression has not been
considered in the previous studies and needs further evaluation of
the regulatory mechanisms at this level.
PCNA has been considered to be a useful marker of proliferating
activity in some tumours (Hall et al, 1990; Jain et al, 1991; Al-
Sheneber et al, 1993), including oesophageal SCC (Hickey et al,
1994; Kinugasa et al, 1996), and appears at the late G1/S boundary
in the cell cycle. Nagel and Vallee (1995) reported that the level of
MT during the mitotic cell cycle of human colon cancer cells
reached its maximum near the G1/S boundary of the cell cycle,
around the onset of DNA synthesis, raising a physiological role for
MT in cell proliferation. Similarly, MT protein expression singly or
in combination with PCNA expression was significantly associated
with poor prognosis in oesophageal SCC in the univariate analysis,
while, in the step-wise multiple regression test, neither MT expres-
sion nor PCNA could be an independent prognostic factor in
oesophageal SCC. Therefore, in the clinical setting, the expression
of MT protein might be a useful marker to identify cell proliferation
in combination with PCNA. However, the predictability of prog-
nosis by MT expression might be associated with other cell cycle
regulatory genes, like p53 (Zheng et al, 1996).
In conclusion, the expression of MT protein and/or mRNA was
positively correlated with tumour metastatic activity. The expression
of MT protein was also correlated with tumour proliferating activity
in the current study. These results indicate that MT mRNA and its
protein may be used as potential markers, which permit us to predict
the metastatic and proliferative activities in oesophageal SCC.
ACKNOWLEDGEMENTS
We would like to thank Dr Paul K Nakane (Microcide
Pharmaceuticals) for valuable advice.
REFERENCES
Abdel-Mageed A and Agrawal KC (1997) Antisense down-regulation of
metallothionein induces growth arrest and apoptosis in human breast carcinoma
cells. Cancer Gene Ther 4: 199–207Adams JC (1981) Heavy metal intensification of DAB-based HRP reaction products.
J Histochem Cytochem 29: 775
Al-Sheneber IF, Shibata HR, Sampalis J and Jothy S (1993) Prognostic significance
of proliferating cell nuclear antigen expression in colorectal cancer. Cancer 71:
1954–1959
Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ and Cherian MG
(1993) Metallothionein in testicular germ cell tumors and drug resistance.
Cancer 72: 3029–3035
Chiu R, Boyle WJ, Meek J, Smeal T, Hunter T and Karin M (1988) The c-fos protein
interacts with jun/AP-1 to stimulate transcription of AP-1 responsive genes.
Cell 54: 541–552
Fresno M, Wu W, Rodriguez JM and Nadji M (1993) Localization of
metallothionein in breast carcinomas. An immunohistochemical study.
Virchows Arch A 423: 215–219
Goulding H, Jasani B, Pereira H, Reid A, Galea M, Bell JA, Elston CW, Robertson
JF, Blamey RW, Nicholson RA, Schmid KW and Ellis IO (1995)
Metallothionein expression in human breast cancer. Br J Cancer 72: 968–972
Haga A, Nagase H, Kito H and Sato T (1996a) Enhanced invasiveness of tumour
cells after host exposure to heavy metals. Eur J Cancer 32A: 2342–2347
Haga A, Nagase H, Kito H and Sato T (1996b) Effect of metallothioneins on
transformation of gelatinase A from human fibroblast WI-38 cells. Cancer Lett
105: 175–180
Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, Barnes DM,
Gillett CE, Camplejohn R, Dover R, Waseem NH and Lane DP (1990)
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin
sections: an index of cell proliferation with evidence of deregulated expression
in some neoplasms. J Pathol 162: 285–294
Hickey K, Grehan D, Reid IM, O’Briain S, Walsh TN and Hennessy TPJ (1994)
Expression of epidermal growth factor receptor and proliferating cell nuclear
antigen predicts response of esophageal squamous cell carcinoma to
chemoradiotherapy. Cancer 74: 1693–1698
Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Igarashi M, Tachibana
M and Nagasue N (1997) Overexpression of metallothionein correlates with
chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology 54:
342–347
Hollstein MC, Metcalf RA, Welsh JA, Montesano R and Harris C C (1990) Frequent
mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA
87: 9958–9961
Hu E, Mueller E, Oliviero S, Papaioannou VE, Johnson R and Spiegelman BM
(1994) Targeted disruption of the c-fos gene demonstrates c-fos-dependent and
-independent pathways for gene expression stimulated by growth factors or
oncogenes. EMBO J 13: 3094–3103
Jain S, Filipe MI, Hall PA, Waseem N, Lane DP and Levison DA (1991) Prognostic
value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol
44: 655–659
Jasani B and Schmid KW (1997) Significance of metallothionein overexpression in
human tumours. Histopathology 31: 211–214
Jasani B and Elmes ME (1991) Immunohistochemical detection of metallothionein.
In: Methods in Enzymology Metallobiochemistry, Part B, Metallothionein and
Related Molecules, Riordan JF and Vallee BL (eds), pp. 95–107. Academic
Press: San Diego
Karin M and Richards RI (1982) Human metallothionein genes – primary structure
of the metallothionein-II gene and a related processed gene. Nature 299:
797–802
Karin M, Eddy RL, Henry WM, Haley LL, Byers MG and Shows TB (1984) Human
metallothionein genes are clustered on chromosome 16. Proc Natl Acad Sci
USA 81: 5494–5498
Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T
and Saijo N (1991) Metallothionein content correlates with the sensitivity of
human small cell lung cancer cell lines to cisplatin. Cancer Res 51: 3237–3242
Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS (1988)
Overexpression of metallothionein confers resistance to anticancer drugs.
Science 241: 1813–1815
Kinugasa S, Tachibana M, Hishikawa Y, Abe S, Yoshimura H, Monden M, Dhar DK
and Nagasue N (1996) Prognostic significance of proliferating cell nuclear
antigen (PCNA) in squamous cell carcinoma of the esophagus. Jpn J Clin
Oncol 26: 405–410
Kitagawa Y, Ueda M, Ando N, Shinozawa Y, Shimizu N and Abe O (1991)
Significance of int-2/hst-1 coamplification as a prognostic factor in patients
with esophageal squamous carcinoma. Cancer Res 51: 1504–1508
Koji T and Brenner RM (1993) Localization of estrogen receptor messenger
ribonucleic acid in rhesus monkey uterus by nonradioactive in situ
hybridization with digoxigenin-labeled oligodeoxynucleotides. Endocrinology
132: 382–392
Koji T and Nakane PK (1996) Recent advances in molecular histochemical
techniques: in situ hybridization and southwestern histochemistry. J Electron
Microsc 45: 119–127
Kondo Y, Kuo S, Watkins SC and Lazo JS (1995) Metallothionein localization and
cisplatin resistance in human hormone-independent prostatic tumor cell lines.
Cancer Res 55: 474–477
Le Beau MM, Diaz MO, Karin M and Rowley JD (1985) Metallothionein gene
cluster is split by chromosome 16 rearrangements in myelomocytic leukaemia.
Nature 313: 709–711
Lee W, Mitchell P and Tjian R (1987) Purified transcription factor AP-1 interacts
with TPA-inducible enhancer elements. Cell 49: 741–752
Lim K, Evans A, Adams M, Fish R, Dhundee J, Dallimore N and Jasani B (1996)
Association of immunohistochemically detectable metallothionein (IDMT)
expression with malignant transformation in cervical neoplasia. J Pathol 178:
48A
Mandard AM, Marnay J, Gignoux M, Segol P, Blanc L, Ollivier JM, Borel B and
Mandard JC (1984) Cancer of the esophagus and associated legions: detailed
pathologic study of 100 esophagectomy specimens. Hum Pathol 15: 660–669
Meltzer SJ, Yin J, Huang Y, McDaniel TK, Newkirk C, Iseri O, Vogelstein B and
Resau JH (1991) Reduction to homozygosity involving p53 in esophageal
cancers demonstrated by polymerase chain reaction. Proc Natl Acad Sci USA
88: 4976–4980
Miyake S, Nagai K, Yoshino K, Oto M, Endo M and Yuasa Y (1994) Point
mutations and allelic deletion of tumor suppressor gene DCC in human
esophageal squamous cell carcinomas and their relation to metastasis. Cancer
Res 54: 3007–3010
Mulder TPJ, Verspaget HW, Janssens AR, De Bruin PAF, Griffioen G and Lamers
CBHW (1990) Neoplasia-related changes of two copper (Cu)/Zinc (Zn)
proteins in the human colon. Free Radical Bio Med 10: 501–506
Nagel WW and Vallee B (1995) Cell cycle regulation of metallothionein in human
colonic cancer cells. Proc Natl Acad Sci USA 92: 579–583
Öfner D, Maier H, Riedmann B, Bammer T, Rumer A, Winde G, Böcker W, Jasani B
and Schmid KW (1994) Immunohistochemical metallothionein expression in
colorectal adenocarcinoma: correlation with tumour stage and patient survival.
Virchows Arch 425: 491–497
Ohshio G, Imamura T, Okada N, Wang ZH, Yamaki K, Kyogoku T, Suwa H,
Yamabe H and Imamura M (1996) Immunohistochemical study of
metallothionein in pancreatic carcinomas. J Cancer Res Clin 122: 351–355
Orrigner MB (1997) Tumors of the esophagus. In: Textbook of Surgery, Sabiston DC
Jr (ed), pp. 744–758. WB Saunders: Philadelphia
Oyama T, Takei H, Hikino T, Iino Y and Nakajima T (1996) Immunohistochemical
expression of metallothionein in invasive breast cancer in relation to
proliferative activity, histology and prognosis. Oncology 53: 112–117
Ransone LJ and Verma IM (1990) Nuclear proto-oncogenes fos and jun. Annu Rev
Cell Biol 6: 539–557
Schmid KW, Ellis IO, Gee JMW, Darke BM, Lees WE, Kay J, Cryer A, Stark JM,
Hittmair A, Öfner D, Dünser M, Margreiter R, Daxenbichler G, Nicholson RI,
Bier B, Böcker W and Jasani B (1993) Presence and possible significance of
immunocytochemically demonstrable metallothionein over-expression in
primary invasive ductal carcinoma of the breast. Virchows Arch A 422:
153–159
Shulte EKW, Lyon HO and Hoyer PE (1992) Simultaneous quantification of DNA
and RNA in tissue sections. A comparative analysis of the methyl green-
pyronin technique with the gallocyanin chromalum and Feulgen procedures
using image cytometry. Histochem J 24: 305–310
Skroch P, Inouye C and Karin M (1991) Regulation of human and yeast
metallothionein gene transcription by heavy metal ions. In: Metallothionein in
Biology and Medicine, Klaassen CD and Suzuki KT (eds), pp. 61–74. CRC
Press: Boca Raton, Florida
Steele GD Jr, Davis S, Yow H, Wong JM, Rivers EN, Summerhayes IC, Ravikumar
TS and Chen LB (1990) Alterations of gene expression in human colorectal
cancer. Arch Surg 25: 493–497
Stracke ML and Liotta LA (1995) Molecular mechanisms of tumor cell metastasis.
In: The Molecular Basis of Cancer, Mendelsohn J, Howley PM, Israel MA and
Liotta LA (eds), pp. 233–247. WB Saunders: Philadelphia
Tohyama C, Suzuki JS, Hemelraad J, Nishimura N and Nishimura H (1993)
Induction of metallothionein and its localization in the nucleus of rat
hepatocytes after partial hepatectomy. Hepatology 18: 1193–1201
Yoshii A, Koji T, Ohsawa N and Nakane PK (1995) In situ localization of 
ribosomal RNAs is a reliable reference for hybridizable RNA in tissue sections.
J Histochem Cytochem 43: 321–328
Zelger B, Hittmair A, Schir M, Öfner C, Öfner D, Fritsch PO, Böcker W, Jasani B
and Schmid KW (1993) Immunohistochemically demonstrated metallothionein
expression in malignant melanoma. Histopathology 23: 257–264
Metallothionein in oesophageal SCC 719
British Journal of Cancer (1999) 81(4), 712–720 © 1999 Cancer Research Campaign720 Y Hishikawa et al
British Journal of Cancer (1999) 81(4), 712–720 © 1999 Cancer Research Campaign
Zelger B, Sidoroff A, Hopfl R, Öfner D, Jasani B and Schmid KW (1994)
Metallothionein expression in nonmelanoma skin cancer. Appl
Immunohistochem 2: 254–260
Zheng H, Liu J, Choo KH, Michalska AE and Klaassen CD (1996) Metallothionein-I
and -II knock-out mice are sensitive to cadmium-induced liver mRNA
expression of c-jun and p53. Toxicol Appl Pharm 136: 229–235